(RTTNews) - Merck & Co Inc. (MRK) on Tuesday said HERTHENA-Lung02 phase 3 study evaluating Daiichi Sankyo and Merck's patritumabderuxtecan in patients with EGFR-mutated non-small cell lung cancer ...
Results that may be inaccessible to you are currently showing.